Buy McDonald's!: Ag...
Health Care: Drugs
Medivation Inc. (MDVN: NASDAQ)
$68.60 -3.04 | -4.25%
02/08/12 - 03:15 PM ET
791.36K / 926.80K
Vol / Avg. Vol:71.88 / 71.64
Open / Prev. Close:67.64 - 71.88
Today's Range:14.32 - 76.65
52 Wk Range:55.38%
Performance YTD:TheStreet Rating:
Portfolios with MDVN
- Portfolio NameUser Type
- User2012 performers
- ContributorFive Drug Stock Winners of ...
- ContributorStocks At New 52-Week Highs...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- ContributorCancer Drug Stocks to Trade...
- ProQVT Financial
- UserASCO 2010 Part 2
- ContributorTop Chart Analysis Plays Fo...
- UserSUPRATRADE RED-0303102110
Latest MDVN Headlines from TheStreet
- Medivation Stock Gaps Up On Today's Open (MDVN) 02.01.12 | 01:02 pm
- Medivation's Prostate Cancer Drug: Survival Benefit With Low Seizure Risk 01.31.12 | 05:01 pm
- Medivation Reaches New 52-Week High (MDVN) 01.31.12 | 12:01 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.27.12 | 01:01 pm
- The Next Big Thing in Biotech: Medivation
01.27.12 | 06:01 am - Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- J.P. Morgan Biotech Confab Live Chat 01.10.12 | 06:01 pm
- Medivation Reaches New 52-Week High (MDVN) 01.09.12 | 10:01 am
- Five Drug Stock Winners of 2011 12.19.11 | 08:12 am
- The Best Biotech CEO of 2011 Is ... 12.14.11 | 06:12 am
Press Releases for MDVN
- Medivation And Pfizer Announce Results From Phase 3 Concert Trial Of Dimebon In Alzheimer’s Disease - Business Wire 01.17.12 | 07:01 am
- Medivation Announces Participation In 13th Annual BIO CEO & Investor Conference - PR Newswire 02.07.11 | 08:02 am
- Medivation Announces Participation In 29th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.11 | 08:01 am
- Medivation Completes Enrollment In Phase 3 'CONCERT' Trial Of Dimebon Added To Donepezil In Patients With Alzheimer's Disease - PR Newswire 12.07.10 | 08:12 am
- Medivation And Astellas Complete Enrollment In Phase 3 Affirm Trial Of MDV3100 In Advanced Prostate Cancer - PR Newswire 11.29.10 | 04:11 pm
- Medivation Announces Third Quarter 2010 Financial Results Teleconference And Webcast On November 5, 2010 - PR Newswire 10.29.10 | 08:10 am
- Medivation Announces Participation In The NewsMakers In The Biotech Industry Conference - PR Newswire 10.19.10 | 08:10 am
- Medivation And Astellas Announce Initiation Of A Second Phase 3 Clinical Trial Of MDV3100 In Advanced Prostate Cancer - PR Newswire 09.29.10 | 08:09 am
- Medivation Announces Participation In The UBS Global Life Sciences Conference - PR Newswire 09.14.10 | 08:09 am
- Medivation Announces Second Quarter 2010 Financial Results Teleconference And Webcast On August 9, 2010 - PR Newswire 08.02.10 | 08:08 am
Partner Headlines for MDVN
- Zacks Bull and Bear of the Day Highlights: Lamar Advertising, HDFC Bank, Medivation, Pfizer and Johnson & Johnson - Press Releases - Zacks 01.19.12 | 09:01 am
- The Top 50 List - Seeking Alpha 12.02.11 | 06:12 pm
- Medivation Back to Neutral - Analyst Blog - Zacks 11.25.11 | 04:11 pm
- Stocks To Watch As Volatility Abounds In Europe - Seeking Alpha 11.16.11 | 08:11 am
- Medivation, Inc. (MDVN) - Bull of the Day - Zacks 11.07.11 | 01:11 am
- Medivation Impresses with MDV3100 - Analyst Blog - Zacks 11.04.11 | 07:11 pm
- Dendreon to Cut 500 Jobs - Analyst Blog - Zacks 09.09.11 | 04:09 pm
- FDA Clears Dendreon 2nd Facility - Analyst Blog - Zacks 06.30.11 | 06:06 pm
- CMS Decision Due on Provenge - Analyst Blog - Zacks 06.14.11 | 10:06 am
- Dendreon Remains Neutral - Analyst Blog - Zacks 06.09.11 | 10:06 am
